Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015-2019
Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015-2019
Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015-2019
Sivextro,
Zerbaxa,
Avycaz,
Zyvox,
Avelox,
Augmentin,
About Us
Spearhead Acuity Business Research & Consulting (SA-BRC) is a premium Life Science business
intelligence and data analytics firm. The SA-BRC team offers a wide range of business intelligence
services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals,
Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the
entire value chain of healthcare industry. Our research and consulting capabilities extend across
several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical
Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.
Our skills and capabilities help put forth the most accurate perspective of the market. We track all
major and minor events that create ripples and affect the life-science market in numerous ways. Our
data modeling process includes the evaluation of impacting events and analyzing other invaluable
sources (public & proprietary) of information and finally reporting results that will influence the
decision making of the readers.
SA-BRC has helped start-ups and market leaders across the globe achieve their revenue goals
strategically in multiple stages such as adoption, pre-launch research, regional analysis, social media
analytics, competitive mapping, market entry and post marketing surveillance. We frequently build
panels of experts for gathering data and invite participants of the healthcare industry to share their
opinions and views on our reports. Our current network of industry experts spans across all major
life-science domains and take pride in keeping ourselves abreast with the latest happenings within
the sphere of Life-Science.
Table of Content
Chapter 1 Preface
1.1
1.2
Research Scope
10
1.1.2 Postulations
11
Methodology of Research
Chapter 2 Prcis
Market Inferences
3.2
Market Drivers
12
13
14
14
16
16
3.1.1 Increasing incidence of hospital and community acquired bacterial infections pushing
growth of brands and generics
16
3.1.2 Improving Legal Framework for provision of Incentives expected to drive growth
16
Market Inhibitors
3.2.1 Limited pipeline drugs and absence of new indication targets may lead to significant
erosion against generics
3.3
2.1
Opportunities
16
16
17
17
17
18
4.1
Introduction
18
4.2
18
4.3
19
4.4
20
4.5
21
4.6
22
4.7
23
4.8
24
4.9
25
26
27
28
29
30
31
32
33
5.1
Introduction
33
5.2
33
5.3
34
5.4
35
5.5
35
5.6
36
5.7
37
5.8
38
5.9
39
40
5.10.1 Finafloxacin
40
5.10.2 Omadacycline
40
5.10.3 Zabofloxacin
40
5.10.4 Ramoplanin
40
5.10.5 Nemonoxacin
41
41
42
6.1
Introduction
42
6.2
43
6.3
44
6.4
45
6.5
46
6.6
47
6.7
48
50
50
51
7.3
51
51
Chapter 8 Epilogue
53
54
List of Figures
FIG. 1
10
FIG. 2
12
FIG. 3
Global Anti-Bacterial Drugs Market Share, by Geography 2014 & 2019 (% Share - US$
Million)
15
FIG. 4
Global Anti-Bacterial Drugs Market Cubicin (daptomycin) Revenues 2013 2019 (US$
Millions)
19
FIG. 5
20
FIG. 6
Global Anti-Bacterial Drugs Market Dificid (fidaxomicin) Revenues 2013 2019 (US$
Millions)
21
FIG. 7
22
23
FIG. 9
23
FIG. 10
24
25
FIG. 12
Global Anti-Bacterial Drugs Market Zyvox (linezolid) Revenues 2013 2019 (US$
Millions)
26
FIG. 13
Global Anti-Bacterial Drugs Market Avelox (moxifloxacin) Revenues 2013 2019 (US$
Millions)
27
FIG. 14
28
29
FIG. 16
Global Anti-Bacterial Drugs Market Invanz (ertapenem) Revenues 2013 2019 (US$
Millions)
30
FIG. 17
Global Anti-Bacterial Drugs Market Tygacil (tigecyline) Revenues 2013 2019 (US$
Millions)
31
Global Anti-Bacterial Drugs Market Other Anti-Bacterial Drug Revenues 2013 2019
(US$ Millions)
32
FIG. 8
FIG. 11
FIG. 15
FIG. 18
FIG. 19
Global Anti-Bacterial Drugs Market Surotomycin Revenues 2013 2019 (US$ Millions) 33
FIG. 20
FIG. 21
34
Global Anti-Bacterial Drugs Market Delafloxacin Revenues 2013 2019 (US$ Millions) 35
FIG. 22
Global Anti-Bacterial Drugs Market Plazomycin Revenues 2013 2019 (US$ Millions)
36
FIG. 23
Global Anti-Bacterial Drugs Market Taksta Revenues 2013 2019 (US$ Millions)
36
FIG. 24
Global Anti-Bacterial Drugs Market Cadazolid Revenues 2013 2019 (US$ Millions)
37
FIG. 25
Global Anti-Bacterial Drugs Market Carbavance Revenues 2013 2019 (US$ Millions) 38
FIG. 26
Global Anti-Bacterial Drugs Market Eravacycline Revenues 2013 2019 (US$ Millions) 39
FIG. 27
North America Anti-Bacterial Drugs Market Revenues 2013 2019 (US$ Millions)
43
FIG. 28
44
FIG. 29
46
FIG. 30
47
FIG. 31
48
FIG. 32
49
FIG. 33
Key Players Market Share: Global Anti-Bacterial Drugs Market, 2014 (%)
50
List of Tables
TABLE 1
13
TABLE 2
Global Anti-Bacterial Drugs Market, by Geography, 2013 - 2019 (US$ Mn) (CAGR: 2015 2019)
42
Chapter 1
1.1
Preface
Research Scope
Chapter Number
Segment
Description
The preface provides a brief overview of the flow of the
research report. The overview is further supplemented by a
graphical representation of the segments analyzed in the
Research Scope
Chapter 1:
Preface
Provides
Research Methodology
Chapter 2:
Prcis
Opportunities
Anti-Bacterial Drugs
Inhibitors
&
SA-BRC
while
Market
Estimations
Current
Marketed
for
Anti-
Bacterial Drugs
analyzed
Teflaro/Zinforo,
Zerbaxa,
in
this
Dificid,
Avycaz,
segment
Dalvance,
Zyvox,
include
Orbactiv,
Avelox,
Cubicin,
Sivextro,
Augmentin,
Chapter 5:
Pipeline Drugs
by
study.
Market Dynamics
adopted
Drivers,
methodology
Chapter 3:
Chapter 4:
the
Bacterial Drugs
Chapter 6:
Geography Market
Size & Forecast
Demographical Analysis
Anti-Bacterial Drugs
Chapter 7:
Recent
Competitive Strategies
Developments
&
developments for the years 2013, 2014 & 2015 and major
competitive strategies adopted by companies in this area
based on events for past 2 years.
Chapter 8:
Postscript
Epilogue
Overview
qualitative
Companies Covered:
Pharmaceuticals,
Therapeutics,
Targanta
Paratek
Pharmaceuticals,
Therapeutics,
Pharmaceuticals,
Actavis
Nektar
Pfizer,
Pharmaceuticals,
Cempra
Optimer
Current Drugs
Pipeline Drugs
Geography
Cubicin
Surotomycin
North
America
Teflaro/Zinforo
Solithromycin
Europe
Dificid
Delafoxacin
Dalvance
Plazomycin
Orbactiv
Asia-Pacific
Latin America
Taksta
Middle-East
Sivextro
Cadazolid
Africa
Zerbaxa
Carbavance
Avycaz
Eravacycline
Zyvox
Avelox
Augmentin
Zocyn/Tazocin
Tygacil
Invanz
10
1.2
Methodology of Research
FIG. 2
Primary Research
Quantitative
Research
Online-web (CATI/CAWI/CAPI)
Telephonic and video conference
Interviewee Location: Multiple
respondents from each of 6 geographies
Interviewee Field Exp.: All Interviewees
were c-level, d-level, VP level and senior
management
Target Information: validation of
secondary findings; cross-verification of
other primary interviews,
Organization Research Institutes,
Manufacturers, Distributors, Resellers
Secondary/Desk Research
Primary Research
Qualitative
Research
Scientist blogs
Online communities/Scientist Forums
Online chat with KOLs/experts
Focused Group Discussions
Target Information: Insights on market
trends, market impact factors, marketing
and awareness programs etc.
Secondary/Desk Research
Spearhead-Acuity Team
Key Findings
Market Forecast
Insight Generation
Data triangulation was done for the information (quantitative/qualitative) collected through
primary and secondary sources. Analysis also included evaluation of all major macro and
microeconomic factors.
Post data triangulation process, the summary of our study was shared with KOLs and industry
experts to suggest further insights to our analysis as well as validate the overall Anti-Bacterial
Drugs Market.
Source: SA-BRC Analysis. **Websites mentioned in the above representation are few examples from our exhaustive list of references that
cannot be compiled in entirety
12
S.No
Company Name
S.No
Company Name
Merck & Co
Pfizer
Cubist Pharmaceuticals
Cempra Pharmaceuticals
Astrazeneca
Actavis Pharmaceuticals
Forest Laboratories
Optimer Pharmaceuticals
10
GlaxoSmithKline (GSK)
11
Mpex Pharmaceuticals
12
Takeda
13
Targanta Therapeutics
14
Durata Therapeutics
15
Nektar Therapeutics
16
Melinta
17
Paratek Pharmaceuticals
18
Source: Proprietary data sources, KOL opinions, Primary Interviews, SA-BRC Analysis
13
Disclaimer:
SA-BRC Market Research is an informative Market Research Company with the sole intention of
sharing market related insights. The information provided in our research reports or on sa-brc.com
though collected through authentic sources, analyzed and cross validated through Key Opinion
Leaders (KOLs) in the industry; neither the company nor authors provide any kind of warranty about
the content both qualitative and quantitative.
Contact
John Whitmore
10685-B Hazelhurst Dr. #17411
Houston, TX 77043
United States
Contac Number: +1(832)-426-3701
Email: john@sa-brc.com, sales@sa-brc.com
Website: www.sa-brc.com
56